SentinusAI® Goes Live: Ainnocence’s AI Platform Turns Sequence Data Into Discovery Decisions in Days

The AI platform for therapeutic antibody and biologics discovery is now open for subscription. SAN FRANCISCO , CA, ...

Akeso, Inc.: Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug ...